

Shuqun Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/842535/publications.pdf>

Version: 2024-02-01

127
papers

4,095
citations

147566

31
h-index

138251

58
g-index

135
all docs

135
docs citations

135
times ranked

4954
citing authors

#	ARTICLE	IF	CITATIONS
1	TGF- β 2-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2012, 22, 291-303.	7.7	466
2	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). <i>Liver Cancer</i> , 2020, 9, 682-720.	4.2	427
3	Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Annals of Surgical Oncology</i> , 2010, 17, 2073-2080.	0.7	239
4	Ubiquitylation of Autophagy Receptor Optineurin by HACE1 Activates Selective Autophagy for Tumor Suppression. <i>Cancer Cell</i> , 2014, 26, 106-120.	7.7	198
5	MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 389-396.	1.8	146
6	A new classification for hepatocellular carcinoma with portal vein tumor thrombus. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2011, 18, 74-80.	1.4	145
7	Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90. <i>Oncology</i> , 2013, 84, 311-318.	0.9	134
8	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 721-730.	3.7	105
9	Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). <i>Liver Cancer</i> , 2020, 9, 28-40.	4.2	93
10	An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study. <i>Hepatology</i> , 2019, 69, 2076-2090.	3.6	89
11	All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer. <i>Journal of Hepatology</i> , 2013, 59, 1255-1263.	1.8	81
12	ICAM-1-Related Noncoding RNA in Cancer Stem Cells Maintains ICAM-1 Expression in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2041-2050.	3.2	76
13	Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4770-4780.	3.3	76
14	ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy. <i>Nature Communications</i> , 2019, 10, 3391.	5.8	75
15	Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. <i>British Journal of Cancer</i> , 2018, 118, 1337-1348.	2.9	62
16	Overexpression of PCK1 Gene Antagonizes Hepatocellular Carcinoma Through the Activation of Gluconeogenesis and Suppression of Glycolysis Pathways. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 344-355.	1.1	57
17	Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. <i>Hpb</i> , 2019, 21, 1687-1696.	0.1	57
18	Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. <i>Oncotarget</i> , 2017, 8, 8867-8876.	0.8	56

#	ARTICLE	IF	CITATIONS
19	FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 2629-2640.	1.3	55
20	Sorafenib enriches epithelial cell adhesion molecule- α positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2- β -AKT cascade. <i>Hepatology</i> , 2015, 62, 1791-1803.	3.6	54
21	Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2188-2196.	0.5	53
22	Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis. <i>Hpb</i> , 2019, 21, 935-944.	0.1	53
23	Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2017, 17, 902.	1.1	48
24	An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study. <i>Oncologist</i> , 2019, 24, e1476-e1488.	1.9	46
25	Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF- κ B signaling pathway. <i>Hepatology</i> , 2010, 51, 535-544.	3.6	42
26	Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy. <i>Hpb</i> , 2016, 18, 549-556.	0.1	42
27	Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. <i>Frontiers in Oncology</i> , 2019, 9, 370.	1.3	42
28	Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. <i>Oncotarget</i> , 2016, 7, 40816-40829.	0.8	38
29	Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion: A Propensity Score Matching Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 1465-1473.	0.7	38
30	Vacuolar Protein Sorting 33B Is a Tumor Suppressor in Hepatocarcinogenesis. <i>Hepatology</i> , 2018, 68, 2239-2253.	3.6	37
31	Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma. <i>BMC Cancer</i> , 2017, 17, 304.	1.1	36
32	Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial. <i>Radiotherapy and Oncology</i> , 2019, 140, 20-25.	0.3	36
33	hPCL3s Promotes Hepatocellular Carcinoma Metastasis by Activating β -Catenin Signaling. <i>Cancer Research</i> , 2018, 78, 2536-2549.	0.4	34
34	PRMT1 Promoted HCC Growth and Metastasis In Vitro and In Vivo via Activating the STAT3 Signalling Pathway. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 1643-1654.	1.1	33
35	CHML promotes liver cancer metastasis by facilitating Rab14 recycle. <i>Nature Communications</i> , 2019, 10, 2510.	5.8	32
36	14-3-3 η promotes hepatocellular carcinoma venous metastasis by modulating hypoxia-inducible factor-1 α . <i>Oncotarget</i> , 2016, 7, 15854-15867.	0.8	31

#	ARTICLE	IF	CITATIONS
37	Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways. <i>Nature Cancer</i> , 2020, 1, 735-747.	5.7	31
38	A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1644-1651.	0.5	29
39	Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study. <i>Hepatology International</i> , 2020, 14, 754-764.	1.9	29
40	Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex. <i>PLoS Biology</i> , 2020, 18, e3000803.	2.6	29
41	Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China. <i>Hepatology International</i> , 2021, 15, 642-650.	1.9	24
42	CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma. <i>Pharmacological Research</i> , 2020, 157, 104800.	3.1	23
43	The Tumor Suppressor Interferon Regulatory Factor 2 Binding Protein 2 Regulates Hippo Pathway in Liver Cancer by a Feedback Loop in Mice. <i>Hepatology</i> , 2020, 71, 1988-2004.	3.6	22
44	Active targeted Janus nanoparticles enable anti-angiogenic drug combining chemotherapy agent to prevent postoperative hepatocellular carcinoma recurrence. <i>Biomaterials</i> , 2022, 281, 121362.	5.7	21
45	Transarterial chemoembolization plus a PD𝘧 inhibitor with or without lenvatinib for intermediate–stage hepatocellular carcinoma. <i>Hepatology Research</i> , 2022, 52, 721-729.	1.8	21
46	BMP10 suppresses hepatocellular carcinoma progression via PTPRS–STAT3 axis. <i>Oncogene</i> , 2019, 38, 7281-7293.	2.6	19
47	Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of �tenin/TCF/LEF signalling. <i>Cell Proliferation</i> , 2019, 52, e12583.	2.4	18
48	PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling. <i>Nature Communications</i> , 2021, 12, 3059.	5.8	18
49	Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 101-127.	2.3	17
50	Association of Preoperative Hypercoagulability with Poor Prognosis in Hepatocellular Carcinoma Patients with Microvascular Invasion After Liver Resection: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 4117-4125.	0.7	16
51	DCAF13 promotes breast cancer cell proliferation by ubiquitin inhibiting <i>PERP</i> expression. <i>Cancer Science</i> , 2022, 113, 1587-1600.	1.7	16
52	The degree of hepatic arterial blood supply of portal vein tumor thrombus in patients with hepatocellular carcinoma and its impact on overall survival after transarterial chemoembolization. <i>Oncotarget</i> , 2017, 8, 79816-79824.	0.8	15
53	Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1709-1718.	0.8	14
54	Liver resection versus transcatheter arterial chemoembolization for the treatment of patients with hepatocellular carcinoma and hepatic vein or inferior vena cava tumor thrombus: A propensity score matching analysis. <i>Hepatology Research</i> , 2019, 49, 441-452.	1.8	13

#	ARTICLE	IF	CITATIONS
55	AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 650963.	1.3	13
56	Co-Upregulation of 14-3-3 η and P-Akt is Associated with Oncogenesis and Recurrence of Hepatocellular Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 1097-1107.	1.1	12
57	MicroRNA-101 modulates cisplatin chemoresistance in liver cancer cells via the DNA-PKcs signaling pathway. <i>Oncology Letters</i> , 2019, 18, 3655-3663.	0.8	12
58	A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 0-0.	0.7	12
59	A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 717-728.	0.7	11
60	Compartmentalized evolution of hepatitis B virus contributes differently to the prognosis of hepatocellular carcinoma. <i>Carcinogenesis</i> , 2021, 42, 461-470.	1.3	11
61	Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. <i>Oncogene</i> , 2021, 40, 5302-5313.	2.6	11
62	Liver resection versus intensity-modulated radiation therapy for treatment of hepatocellular carcinoma with hepatic vein tumor thrombus: a propensity score matching analysis. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 646-660.	0.7	11
63	Epithelial V α 1 μ antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB2-PI3K-AKT pathway. <i>Cancer Science</i> , 2020, 111, 1500-1513.	1.7	11
64	AGK regulates the progression to NASH by affecting mitochondria complex I function. <i>Theranostics</i> , 2022, 12, 3237-3250.	4.6	11
65	A novel classification in predicting prognosis and guiding postoperative management after R0 liver resection for patients with hepatocellular carcinoma and microvascular invasion. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1348-1355.	0.5	11
66	Upregulation of Spondin-2 protein expression correlates with poor prognosis in hepatocellular carcinoma. <i>Journal of International Medical Research</i> , 2019, 47, 569-579.	0.4	10
67	In-hospital Mortality after Surgical Resection in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus. <i>Journal of Cancer</i> , 2019, 10, 72-80.	1.2	9
68	Loss of STAT5A promotes glucose metabolism and tumor growth through miRNA-23a-AKT signaling in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2021, 15, 710-724.	2.1	9
69	Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5615-5627.	1.6	9
70	Engineering of Yin Yang-like nanocarriers for varisized guest delivery and synergistic eradication of patient-derived hepatocellular carcinoma. <i>Nanoscale Horizons</i> , 2019, 4, 1046-1055.	4.1	8
71	Thrombocytopenia: A prognostic factor for hepatocellular carcinoma patients with portal vein tumor thrombus after hepatectomy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1214-1221.	1.4	8
72	The impact of portal vein tumor thrombus on long-term survival after liver resection for primary hepatic malignancy. <i>Hpb</i> , 2020, 22, 1025-1033.	0.1	8

#	ARTICLE	IF	CITATIONS
73	A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk. <i>EBioMedicine</i> , 2020, 52, 102638.	2.7	8
74	Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study. <i>European Journal of Surgical Oncology</i> , 2021, , .	0.5	8
75	The Intracellular HBV DNAs as Novel and Sensitive Biomarkers for the Clinical Diagnosis of Occult HBV Infection in HBeAg Negative Hepatocellular Carcinoma in China. <i>PLoS ONE</i> , 2014, 9, e107162.	1.1	8
76	Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China. <i>Hpb</i> , 2022, 24, 1063-1073.	0.1	8
77	Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. <i>Frontiers in Oncology</i> , 2022, 12, 839605.	1.3	8
78	Impact of splenomegaly and splenectomy on prognosis in hepatocellular carcinoma with portal vein tumor thrombus treated with hepatectomy. <i>Annals of Translational Medicine</i> , 2021, 9, 247-247.	0.7	7
79	Development and validation of an online calculator to predict early recurrence and long-term survival in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 1214-1225.	1.4	7
80	Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0â€“A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching analysis. <i>Hepatology International</i> , 2022, 16, 892-905.	1.9	7
81	Hilar cholangiocarcinoma with synchronous metastases to breast and skeletal muscle: A case report and literature review. <i>Chinese-German Journal of Clinical Oncology</i> , 2006, 5, 216-218.	0.1	6
82	Association between HBV Pre-S mutations and the intracellular HBV DNAs in HBsAg-positive hepatocellular carcinoma in China. <i>Clinical and Experimental Medicine</i> , 2015, 15, 483-491.	1.9	6
83	Hepatocellular carcinoma with hepatic vein invasion should not be considered a contraindication for liver resection. <i>Hepatology</i> , 2018, 67, 804-805.	3.6	6
84	Identification of portal vein tumor thrombus with an independent clonal origin in hepatocellular carcinoma via multi-omics data analysis. <i>Cancer Biology and Medicine</i> , 2019, 16, 147.	1.4	6
85	All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial. <i>Trials</i> , 2019, 20, 245.	0.7	6
86	Long-Term Outcomes of Anatomic Versus Nonanatomic Resection in Hepatocellular Carcinoma Patients with Bile Duct Tumor Thrombus: A Propensity Score Matching Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 7686-7695.	0.7	6
87	Experimental study on enhancement of the metastatic potential of portal vein tumor thrombus-originated hepatocellular carcinoma cells using portal vein serum. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014, 26, 588-95.	0.7	6
88	A novel online calculator to predict recurrence risk in patients with distal cholangiocarcinoma after radical pancreaticoduodenectomy. <i>Journal of Surgical Oncology</i> , 2022, 125, 377-386.	0.8	6
89	Image-matching digital macro-slideâ€“a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma. <i>Hepatology International</i> , 2022, 16, 381-395.	1.9	6
90	Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?. <i>Hepatology</i> , 2018, 68, 786-786.	3.6	5

#	ARTICLE	IF	CITATIONS
91	NET1 promotes HCC growth and metastasis in vitro and in vivo via activating the Akt signaling pathway. <i>Aging</i> , 2021, 13, 10672-10687.	1.4	5
92	Prognostic Value of Microvascular Invasion in Eight Existing Staging Systems for Hepatocellular Carcinoma: A Bi-Centeric Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 726569.	1.3	5
93	Thrombus-First Surgery for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1973-1979.	0.9	4
94	Nujiangexanthone A Inhibits Hepatocellular Carcinoma Metastasis via Down Regulation of Cofilin 1. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 644716.	1.8	4
95	Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 949-958.	0.7	4
96	Scinderin suppresses cell proliferation and predicts the poor prognosis of hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 19, 2011-2020.	0.8	4
97	Comparison of different surgical interventions for hepatocellular carcinoma with bile duct tumor thrombus: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1567-1567.	0.7	4
98	Expression of the Glypican-3 Gene in α -fetoprotein-negative Human Hepatocellular Carcinoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2005, 4, 262-266.	0.1	3
99	Surveillance for Early-Stage Hepatocellular Carcinoma by α Ultrasound Plus Alpha-Fetoprotein Measurement: More Details, More Significance. <i>Gastroenterology</i> , 2018, 155, 1274-1275.	0.6	3
100	Robotic pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: A large-scale study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 942-952.	1.4	3
101	A Multidisciplinary Team Approach to the Management of Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Oncologist</i> , 2020, 25, e998.	1.9	3
102	Typing of biliary tumor thrombus influences the prognoses of patients with hepatocellular carcinoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 808-815.	1.4	3
103	Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis. <i>Hpb</i> , 2022, 24, 547-557.	0.1	3
104	The effect of bile duct tumor thrombus on the long-term prognosis of hepatocellular carcinoma patients after liver resection: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1683-1683.	0.7	3
105	A serological scoring system to predict lymph node metastasis in patients with hepatocellular carcinoma. <i>Hpb</i> , 2019, 21, 335-344.	0.1	2
106	ASO Author Reflections: Preoperative Hypercoagulability Predicts Poor Prognosis in Hepatocellular Carcinoma Patients with Microvascular Invasion After Hepatectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 806-807.	0.7	2
107	Comment on "The Virtual Hepatectomy Changed the Practice of Liver Surgery: More Details, More Significance". <i>Annals of Surgery</i> , 2019, 270, e32-e33.	2.1	2
108	Gene copy number variations in the leukocyte genome of hepatocellular carcinoma patients with integrated hepatitis B virus DNA. <i>Oncotarget</i> , 2016, 7, 8006-8018.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Prognostic Comparison Between Liver Resection and Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Bile Duct Tumor Thrombus: A Propensity-Score Matching Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 835559.	1.3	2
110	Robotic versus open pancreaticoduodenectomy for distal cholangiocarcinoma: a multicenter propensity score-matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 8237-8248.	1.3	2
111	Application of cystoscope in surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. <i>World Journal of Gastroenterology</i> , 2016, 22, 5297.	1.4	1
112	ASO Author Reflections: The Role of Postoperative Adjuvant Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Hepatic Vein Invasion. <i>Annals of Surgical Oncology</i> , 2019, 26, 709-710.	0.7	1
113	A stable and reliable animal model for hepatocellular carcinoma with portal vein tumor thrombus. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 21, 90-90.	0.6	1
114	A nomogram based on combining systemic and hepatic inflammation markers for predicting microscopic bile duct tumour thrombus in hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 272.	1.1	1
115	Concurrent bile duct resection versus concomitant thrombectomy for hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 457-457.	0.7	1
116	Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 3551-3560.	0.9	1
117	Surgical resection for hepatocellular carcinoma with bile duct tumor thrombus. <i>Surgery</i> , 2021, 169, 1424-1426.	1.0	1
118	Association of Preoperative Coagulability With Incidence and Extent of Portal Vein Tumor Thrombus and Survival Outcomes in Hepatocellular Carcinoma After Hepatectomy: A Large-Scale, Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 697073.	1.3	1
119	Step-by-step and orderly lowering of the height of inferior vena cava tumor thrombus is the key to robot-assisted thrombectomy for Mayo III/IV tumor thrombus. <i>BMC Cancer</i> , 2022, 22, 151.	1.1	1
120	Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study. <i>Hpb</i> , 2022, , .	0.1	1
121	Developmental artificial neural network model to evaluate the preoperative safe limit of future liver remnant volume for HCC combined with clinically significant portal hypertension. <i>Future Oncology</i> , 2022, 18, 2683-2694.	1.1	1
122	Reply. <i>Hepatology</i> , 2019, 70, 1878-1879.	3.6	0
123	Hepatocellular Carcinoma with Portal Vein Tumor Thrombus versus Hepatocellular Carcinoma with Biliary Tumor Thrombus: Better or Worse Prognoses? [Letter]. <i>Cancer Management and Research</i> , 2021, Volume 13, 987-988.	0.9	0
124	ASO Author Reflections: Treatment for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus—Anatomic Resection Should Be Recommended. <i>Annals of Surgical Oncology</i> , 2021, 28, 7696-7697.	0.7	0
125	ASO Author Reflections: Impact of Bile Duct Tumor Thrombus in Hepatocellular Carcinoma—Does it Influence Staging Systems?. <i>Annals of Surgical Oncology</i> , 2022, 29, 959-959.	0.7	0
126	ASO Visual Abstract: Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients—A Propensity Score-Matching Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 771-771.	0.7	0

#	ARTICLE	IF	CITATIONS
127	Reply to: Letter to the Editor "Association of type 2 diabetes mellitus with incidences of microvascular invasion and survival outcomes in hepatitis B virus-related hepatocellular carcinoma after liver resection: A multicenter study", European Journal of Surgical Oncology, 2022, , .	0.5	0